Overview

Open-Label Extension Study of BION-1301 in IgA Nephropathy

Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label extension (OLE) study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of BION-1301 in adults with IgA nephropathy
Phase:
Phase 2
Details
Lead Sponsor:
Chinook Therapeutics, Inc.